Table 5

Variable	n(%)	P-value^*
VL^§ diagnosis		0.016
Direct identification of the parasite	22(73.3)
Indirect method (immunological)	8 (26.7)
Myelogram		0.011
Yes	19(63.3)
No	11(26.7)
Antigen rk39^¶ isolation		0.000
Yes	5 (16.7)
No	25(83.3)
PCR^♯		0.000
Yes	1(3.3)
No	29(96.7)
Spleen Biopsy		0.000
Yes	2(6.7)
No	28(23.3)
Use of amphotericin		0.000
Liposomal amphotericin B	28 (93.3)
Amphotericin B	2(6.7)
Use of N-methylglucamine		0.005
Yes	7 (23.3)
No	21(66.7)
VL relapse		0.016
Yes	8 (26.7)
No	22(73.3)
Patients with VL remission		0.001
Yes	24(80.0)
No	6 (20.0)
Deceased patients		0.000
Yes	5 (16.7)
No	25(83.3)
Patients with VL remission and graft loss		0.099
Yes	10(33.3)
No	20(66.7)
Patients with VL remission and graft dysfunction		0.016
Yes	22(73.3)
No	8 (26.7)
Patients with VL remission and return to dialysis		0.099
Yes	10(33.3)
No	20(66.7)

VL^§: visceral leishmaniasis; rK39^¶ : antigen extracted from Leishmania sp.; PCR^♯: polymerase chain reaction. ^*χ² test. Categorial variables are reported as n (%)

Table 5: Methods for diagnosis, treatment, and response to therapeutics in 30 renal transplant recipients with post-transplantation Visceral Leishmaniasis.